Long-term (LT) Exposure to low-dose prednisone given with or without abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients

被引：0
|
作者：
Ryan, Charles J. [1 ]
Chi, Kim N. [2 ]
de Bono, Johann S. [3 ,4 ]
Fizazi, Karim [5 ]
Gomella, Leonard G. [6 ,7 ]
Miller, Kurt [10 ]
Rathkopf, Dana E. [8 ,9 ,11 ]
Scher, Howard I. [6 ,7 ]
Shore, Neal D. [10 ]
De Porre, Peter [8 ,9 ,11 ]
Londhe, Anil [8 ,9 ,11 ]
McGowan, Tracy [12 ]
Pelhivanov, Nonko [8 ,9 ,11 ]
Charnas, Robert [8 ,9 ,11 ]
Todd, Mary B. [13 ]
Montgomery, Bruce [14 ]
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Inst Canc Res, London, England
[4] Univ Paris 11, Inst Gustave Roussy, Paris, France
[5] Univ Paris 11, Inst Gustave Roussy, Paris, France
[6] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[7] Charite Univ Med Berlin, Berlin, Germany
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Weill Cornell Med Coll, New York, NY USA
[10] Atlantic Urol Clin, Carolina Urol Res Ctr, Panama City, Panama
[11] Janssen Res & Dev, London, England
[12] Janssen Sci Affairs, London, England
[13] Janssen Global Serv, Titusville, NJ USA
[14] Univ Washington, Seattle, WA 98195 USA
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [21] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] Low-dose abiraterone with fatty food versus standard dose abiraterone in metastatic castration-resistant prostate cancer
    Shaherose, S.
    Charu, G. Katta
    Santa, A.
    Rajappa, S. J.
    Mohan, K.
    Boyella, P. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1496 - S1496
  • [24] Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    A. W. Tolcher
    K. N. Chi
    N. D. Shore
    R. Pili
    A. Molina
    M. Acharya
    T. Kheoh
    J. J. Jiao
    M. Gonzalez
    A. Trinh
    C. Pankras
    N. Tran
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 70 : 305 - 313
  • [25] Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    Tolcher, A. W.
    Chi, K. N.
    Shore, N. D.
    Pili, R.
    Molina, A.
    Acharya, M.
    Kheoh, T.
    Jiao, J. J.
    Gonzalez, M.
    Trinh, A.
    Pankras, C.
    Tran, N.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 305 - 313
  • [26] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients
    Martinez Lago, N.
    Anido, U.
    Vieito, M.
    Varela-Ponte, R.
    Carmona, M.
    Rodriguez, C.
    Cortegoso, A.
    Candamio, S.
    Lopez-Lopez, R.
    Leon, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S705 - S706
  • [28] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience
    Leibowitz-Amit, Raya
    Atenafu, Eshetu G.
    Seah, Jo-An
    Templeton, Arnoud J.
    Vera-Badillo, Francisco Emilio
    Solow, Henry L.
    Knox, Jennifer J.
    Sridhar, Srikala S.
    Tannock, Ian
    Joshua, Anthony Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [30] Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    Yu, Margaret K.
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene Connelly
    Gonzalez, Martha
    Trudel, Geralyn Carol
    Chauhan, Vijay
    Jiao, Juhui James
    Saad, Fred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345